{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:48:11Z","timestamp":1789469291114,"version":"build-2803163510"},"reference-count":164,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/2230-8210.196029","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T06:39:43Z","timestamp":1482302383000},"page":"210","source":"Crossref","is-referenced-by-count":18,"title":["Safe and pragmatic use of sodium\u2013glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement"],"prefix":"10.4103","volume":"21","author":[{"given":"Sanjay","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AH","family":"Aamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Tofail","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MohammodFeroz","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ManashP","family":"Baruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uditha","family":"Bulugahapitiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AK","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Gunatilake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SaeedA","family":"Mahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Faruque","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NazmulKabir","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SAbbas","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Shakya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Shreshta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manilka","family":"Sumanatilleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AG","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AchiniMadushani","family":"Wijesinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.196029-1","first-page":"3","volume-title":"Standards of medical care in diabetes-2016 abridged for primary care providers","author":"American","year":"2016","journal-title":"Clin Diabetes"},{"key":"key-10.4103\/2230-8210.196029-2","first-page":"84","volume-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary","author":"Garber","year":"2016","journal-title":"Endocr Pract"},{"key":"key-10.4103\/2230-8210.196029-3","first-page":"2298","volume-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","author":"G\u00e6de","year":"2016","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.196029-4","first-page":"1047","volume-title":"Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-5","first-page":"1097","volume-title":"Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes","author":"Lam","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2230-8210.196029-6","first-page":"1497","volume-title":"Classification of non-insulin glucose lowering drugs","author":"Kalra","year":"2016","journal-title":"J Pak Med Assoc"},{"key":"key-10.4103\/2230-8210.196029-7","first-page":"257","volume-title":"Pharmacotherapy in type 2 diabetes: A functional schema for drug classification","author":"McGill","year":"2012","journal-title":"Curr Diabetes Rev"},{"key":"key-10.4103\/2230-8210.196029-8","first-page":"15","volume-title":"On the horizon: New oral therapies for type 2 diabetes mellitus","author":"Ukrainski","year":"2013","journal-title":"Int J Diabetol Vasc Dis Res"},{"key":"key-10.4103\/2230-8210.196029-9","first-page":"1335","volume-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"key-10.4103\/2230-8210.196029-10","unstructured":"Pharmaceuticals and Medical Devices Agency, Japan; 2013. Available from: http:\/\/www.pmda.go.jp\/english\/index.html. [Last accessed on 2016 Aug 22]."},{"key":"key-10.4103\/2230-8210.196029-11","first-page":"1","volume-title":"RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015","author":"Madhu","year":"2015","journal-title":"Int J Diabetes Dev Ctries"},{"key":"key-10.4103\/2230-8210.196029-12","unstructured":"Guidelines for the management of type 2 diabetes mellitus in Pakistan. http:\/\/www.pakendosociety.org\/dmguidelines\/. [Last accessed on 2016 Jun 29]."},{"key":"key-10.4103\/2230-8210.196029-13","unstructured":"Clinical Practice Guidelines: Management of Diabetes Mellitus. Sri Lanka. http:\/\/wwwslcoglk\/img\/guidelines\/Other%20national%20Gidelines\/Physicians\/Book%201\/Management%20of%20Diabetes%20Mellituspdf. [Last accessed on 2016 Jun 29]."},{"key":"key-10.4103\/2230-8210.196029-14","first-page":"807","volume-title":"Burden of non-communicable diseases in South Asia","author":"Ghaffar","year":"2004","journal-title":"BMJ"},{"key":"key-10.4103\/2230-8210.196029-15","unstructured":"IDF Diabetes Atlas- South-Asian Region. Available from: http:\/\/www.diabetesatlas.org\/resources\/2015-atlas.html. [Last accessed on 2016 Jul 05]."},{"key":"key-10.4103\/2230-8210.196029-16","first-page":"380","volume-title":"Prevalence and trends of the diabetes epidemic in South Asia: A systematic review and meta-analysis","author":"Jayawardena","year":"2012","journal-title":"BMC Public Health"},{"key":"key-10.4103\/2230-8210.196029-17","first-page":"53","volume-title":"Diabetes in South Asians: Is the phenotype different?","author":"Unnikrishnan","year":"2014","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.196029-18","unstructured":"World Health Organization. Global Health Observatory (GHO) Data; 2008. Available from: http:\/\/www.who.int\/gho\/ncd\/risk_factors\/obesity_text\/en\/. [Last accessed on 2016 Jul 05]."},{"key":"key-10.4103\/2230-8210.196029-19","unstructured":"World Health Organization Regional Office for South-East Asia. Cardiovascular Diseases Fact Sheet, Department of Noncommunicable Diseases and Environmental Health. Available from: http:\/\/www.searo.who.int\/india\/topics\/cardiovascular_diseases\/factsheet_cvd_2015.pdf. [Last accessed on 2016 Sep 23]."},{"key":"key-10.4103\/2230-8210.196029-20","unstructured":"World Health Organization Regional Office of South-East Asia. High Blood Pressure Global and Regional Overview. Available from: http:\/\/www.searo.who.int\/entity\/world_health_day\/leaflet_burden_hbp_whd2013.pdf. [Last accessed on 2016 Jul 05]."},{"key":"key-10.4103\/2230-8210.196029-21","first-page":"753","volume-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"key-10.4103\/2230-8210.196029-22","first-page":"136","volume-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications","author":"Gerich","year":"2010","journal-title":"Diabet Med"},{"key":"key-10.4103\/2230-8210.196029-23","first-page":"32","volume-title":"Active sugar transport in health and disease","author":"Wright","year":"2007","journal-title":"J Intern Med"},{"key":"key-10.4103\/2230-8210.196029-24","first-page":"125","volume-title":"Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose","author":"Farber","year":"1951","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.196029-25","first-page":"510","volume-title":"The sodium\/glucose cotransport family SLC5","author":"Wright","year":"2004","journal-title":"Pflugers Arch"},{"key":"key-10.4103\/2230-8210.196029-26","first-page":"3324","volume-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.196029-27","first-page":"237","volume-title":"Glucose transporters: Structure, function and consequences of deficiency","author":"Brown","year":"2000","journal-title":"J Inherit Metab Dis"},{"key":"key-10.4103\/2230-8210.196029-28","first-page":"993","volume-title":"Molecular physiology of sodium-glucose cotransporters","author":"Hediger","year":"1994","journal-title":"Physiol Rev"},{"key":"key-10.4103\/2230-8210.196029-29","first-page":"429","volume-title":"The correlation of hemoglobin A1c to blood glucose","author":"Sikaris","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"key-10.4103\/2230-8210.196029-30","first-page":"195","volume-title":"Sodium glucose co-transporter type 2 (SGLT2) inhibitors: Targeting the kidney to improve glycemic control in diabetes mellitus","author":"Bays","year":"2013","journal-title":"Diabetes Ther"},{"key":"key-10.4103\/2230-8210.196029-31","first-page":"499","volume-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.196029-32","first-page":"1730","volume-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-33","first-page":"355","volume-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"key-10.4103\/2230-8210.196029-34","first-page":"3427","volume-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.196029-35","first-page":"669","volume-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-36","first-page":"S20","volume-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","author":"List","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"key-10.4103\/2230-8210.196029-37","unstructured":"Invokana Prescribing Information; May, 2016. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204042s015s019lbl.pdf. [Last accessed on 2016 Jul 05]."},{"key":"key-10.4103\/2230-8210.196029-38","unstructured":"Farxiga Prescribing Information; December, 2015. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/202293s008lbl.pdf. [Last accessed on 2016 Jul 05]."},{"key":"key-10.4103\/2230-8210.196029-39","unstructured":"Jardiance Prescribing Information; March, 2016. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204629s005lbl.pdf. [Last accessed on 2016 Jul 05]."},{"key":"key-10.4103\/2230-8210.196029-40","first-page":"2117","volume-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.196029-41","first-page":"1","volume-title":"Fuel metabolism in starvation","author":"Cahill","year":"2006","journal-title":"Annu Rev Nutr"},{"key":"key-10.4103\/2230-8210.196029-42","first-page":"1108","volume-title":"CV protection in the EMPA-REG OUTCOME trial: A \u201cthrifty substrate\u201d hypothesis","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-43","first-page":"395","volume-title":"Regulation of hepatic fatty acid oxidation and ketone body production","author":"McGarry","year":"1980","journal-title":"Annu Rev Biochem"},{"key":"key-10.4103\/2230-8210.196029-44","first-page":"1115","volume-title":"Can a Shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study.A unifying hypothesis?","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-45","first-page":"1333","volume-title":"SGLT2 inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms?","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.196029-46","first-page":"725","volume-title":"Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect","author":"Kalra","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-47","first-page":"79","volume-title":"Choice of glucose-lowering therapy \u2013 A metabolic fulcrum-based approach","author":"Kalra","year":"2015","journal-title":"US Endocrinol"},{"key":"key-10.4103\/2230-8210.196029-48","doi-asserted-by":"crossref","unstructured":"Kalra S, Gupta Y, Patil S. Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions. Indian J Endocrinol Metab 2015;19:426-9.","DOI":"10.4103\/2230-8210.152793"},{"key":"key-10.4103\/2230-8210.196029-49","first-page":"524","volume-title":"Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis","author":"Kalra","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-50","first-page":"509","volume-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.196029-51","first-page":"1167","volume-title":"Role of AMP-activated protein kinase in mechanism of metformin action","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.196029-52","first-page":"3997","volume-title":"Diabetic kidney disease: From physiology to therapeutics","author":"Mora-Fern\u00e1ndez","year":"2014","journal-title":"J Physiol"},{"key":"key-10.4103\/2230-8210.196029-53","first-page":"114","volume-title":"Preventing diabetic renal disease: The potential reno-protective effects of SGLT2 inhibitors","author":"Maltese","year":"2015","journal-title":"Br J Diabetes Vasc Dis"},{"key":"key-10.4103\/2230-8210.196029-54","first-page":"587","volume-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"key-10.4103\/2230-8210.196029-55","first-page":"1036","volume-title":"Beat it early: Putative renoprotective haemodynamic effects of oral hypoglycaemic agents","author":"Gnudi","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.4103\/2230-8210.196029-56","first-page":"323","volume-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.196029-57","unstructured":"Clinical Study Synopsis for Public Disclosure. Available from: http:\/\/www.trials.boehringer-ingelheim.com\/content\/dam\/internet\/opu\/clinicaltrial\/com_EN\/results\/1245\/1245.25_c02695839-01_DR.pdf. [Last accessed in 2016 Sep 23]."},{"key":"key-10.4103\/2230-8210.196029-58","first-page":"463","volume-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-59","doi-asserted-by":"crossref","unstructured":"Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2016. pii: ASN.2016030278.","DOI":"10.1681\/ASN.2016030278"},{"key":"key-10.4103\/2230-8210.196029-60","first-page":"391","volume-title":"The effect of dapagliflozin on renal function in patients with type 2 diabetes","author":"Kohan","year":"2016","journal-title":"J Nephrol"},{"key":"key-10.4103\/2230-8210.196029-61","first-page":"590","volume-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-62","unstructured":"FDA Drug Safety Communication: FDA Strengthens Kidney Warnings for Diabetes Medicines Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR); June, 2016. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm505860.htm. [Last accessed in 2016 Sep 23]."},{"key":"key-10.4103\/2230-8210.196029-63","unstructured":"FDA Briefing Document. (sNDA) 204629, Empagliflozin (JARDIANCE) Tablets, and sNDA 206111, Empagliflozin and Metformin Hydrochloride (SYNJARDY) Tablets. Boehringer Ingelheim Pharmaceuticals, and Metabolic Drug Advisory Inc., Endocrine Committee Meeting; 28 June, 2016. Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM508422.pdf. [Last accessed in 2016 Oct 17]."},{"key":"key-10.4103\/2230-8210.196029-64","first-page":"601","volume-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.196029-65","first-page":"e30555","volume-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"key-10.4103\/2230-8210.196029-66","first-page":"2154","volume-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-67","first-page":"1296","volume-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: Results of a randomized trial","author":"Stein","year":"2014","journal-title":"Metabolism"},{"key":"key-10.4103\/2230-8210.196029-68","first-page":"e009417","volume-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: A systematic review and network meta-analysis","author":"Shyangdan","year":"2016","journal-title":"BMJ Open"},{"key":"key-10.4103\/2230-8210.196029-69","first-page":"58","volume-title":"Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized double-blind controlled trials","author":"Berhan","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"key-10.4103\/2230-8210.196029-70","first-page":"457","volume-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-71","first-page":"88","volume-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary.The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)","author":"Ryd\u00e9n","year":"2007","journal-title":"Eur Heart J"},{"key":"key-10.4103\/2230-8210.196029-72","first-page":"e1461","volume-title":"Triple therapy in type 2 diabetes; a systematic review and network meta-analysis","author":"Downes","year":"2015","journal-title":"PeerJ"},{"key":"key-10.4103\/2230-8210.196029-73","first-page":"783","volume-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-74","first-page":"137","volume-title":"Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting","author":"Baruah","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-75","first-page":"372","volume-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India","author":"Prasanna","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-76","first-page":"40","volume-title":"A prospective analysis of the efficacy and safety of sodium glucose cotransporter 2 inhibitors: Real World Evidence from Clinical Practice in India","author":"Sosale","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/2230-8210.196029-77","first-page":"581","volume-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","author":"Del","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-78","first-page":"2217","volume-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-79","unstructured":"Salsali A, Ridderstrale M, Toorawa R, Andersen KR, Woerle HJ. Empagliflozin Compared with Glimepiride as Add-on to Metformin for 4 Years in Patients with T2DM, Greater Red HbA1c and Hypoglycemia. American Diabetes Association 76th Scientific Sessions, 10-14 June, 2016; New Orleans, Louisiana."},{"key":"key-10.4103\/2230-8210.196029-80","first-page":"163","volume-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study","author":"Stenl\u00f6f","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2230-8210.196029-81","first-page":"208","volume-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key-10.4103\/2230-8210.196029-82","first-page":"356","volume-title":"Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C","author":"Skolnik","year":"2016","journal-title":"Postgrad Med"},{"key":"key-10.4103\/2230-8210.196029-83","first-page":"372","volume-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-84","doi-asserted-by":"crossref","unstructured":"Lorenzi M, Jon Ploug U, Langer J, Skovgaard R, Jansen J. Liraglutide Versus SGLT2 Inhibitors in People with Type 2 Diabetes: A Network Meta-analysis. Poster \u2013 The World Diabetes Conference, 30 November-04 December 2015; Vancouver, Canada.","DOI":"10.1007\/s13300-016-0217-4"},{"key":"key-10.4103\/2230-8210.196029-85","unstructured":"Davidson JA, Schernthaner G, Hieronymus L, Jodon H, Vijapurkar U, Meininger G, et al. Canagliflozin is Superior to Sitagliptin in Reducing Both A1C and Body Weight in Patients with Type 2 Diabetes Mellitus. Poster \u2013 The 97th Annual Meeting and Expo of the Endocrine Society (ENDO), 05-08 March, 2015; San Diego, California."},{"key":"key-10.4103\/2230-8210.196029-86","unstructured":"Langslet G, Davidson JA, Valentine V, Vijapurkar U, Canovatchel W, Meininger G. Canagliflozin reduces both HbA1c and body weight in patients with type 2 diabetes mellitus on background metformin. Poster \u2013 50th Annual meeting of EASD, September 2014; Austria."},{"key":"key-10.4103\/2230-8210.196029-87","first-page":"2582","volume-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.196029-88","unstructured":"Stein L, Schroeder M, Diels J, Hamilton G, Canovatchel W. A Greater Proportion of People with Type 2 Diabetes Inadequately Controlled on Metformin Reach the Composite Target of HbA1c<7.5% (59 mmol\/mol) and \u22653% Body Weight Reduction when Treated with Either Canagliflozin 100 or 300 mg as Compared with Sitagliptin 100 mg at 52 weeks. Poster \u2013 The Diabetes UK Professional Conference; 11-15 March, 2015, London, UK."},{"key":"key-10.4103\/2230-8210.196029-89","doi-asserted-by":"crossref","unstructured":"Taieb V, Pacou M, Schroeder M, Nielsen AT, Schubert A, Neslusan C. A Network Meta-analysis to Assess the Longer-term Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Inadequately Controlled on Metformin. Poster \u2013 The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress; 07-11 November, 2015, Milan, Italy.","DOI":"10.1016\/j.jval.2015.09.2046"},{"key":"key-10.4103\/2230-8210.196029-90","first-page":"269","volume-title":"Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin","author":"Leiter","year":"2016","journal-title":"Diabetes Ther"},{"key":"key-10.4103\/2230-8210.196029-91","doi-asserted-by":"crossref","unstructured":"van Sanden S, Diels J, Pascal G, Nielsen AT. Bayesian Network Meta-analysis to Assess Relative Efficacy of Canagliflozin Versus Glucagon-like Peptide-1 Receptor Agonists in Dual and Triple Therapy in Patients With Type 2 Diabetes Mellitus. Poster \u2013 The 20th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 16-20 May, 2015, Philadelphia, Pennsylvania.","DOI":"10.1016\/j.jval.2015.03.319"},{"key":"key-10.4103\/2230-8210.196029-92","doi-asserted-by":"crossref","unstructured":"Nauck MA, Del Prato S, Meier JJ, Dur\u00e1n-Garc\u00eda S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.","DOI":"10.2337\/dc11-0606"},{"key":"key-10.4103\/2230-8210.196029-93","first-page":"691","volume-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key-10.4103\/2230-8210.196029-94","doi-asserted-by":"crossref","unstructured":"Pacou M, Taieb V, Abrams K, Diels J, van Sanden S, Garg M, et al. Bayesian Network Meta-analysis to Assess the Relative Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus (t2dm) Inadequately Controlled on Metformin and Sulphonylurea (met+su). Poster \u2013 The 16th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); November, 2013, Dublin, Ireland.","DOI":"10.1016\/j.jval.2013.08.1747"},{"key":"key-10.4103\/2230-8210.196029-95","first-page":"3396","volume-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-96","doi-asserted-by":"crossref","unstructured":"Jabbour SA, Hardy E, Sugg J, Parikh S; Study Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740-50.","DOI":"10.2337\/dc13-0467"},{"key":"key-10.4103\/2230-8210.196029-97","first-page":"147","volume-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-98","first-page":"2009","volume-title":"Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes","author":"Mathieu","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-99","first-page":"1075","volume-title":"Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes","author":"Matthaei","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-100","first-page":"384","volume-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-101","first-page":"403","volume-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-102","first-page":"1815","volume-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-103","doi-asserted-by":"crossref","unstructured":"Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 2012;156:405-15.","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"key-10.4103\/2230-8210.196029-104","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM Trial Investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48.","DOI":"10.1111\/dom.12503"},{"key":"key-10.4103\/2230-8210.196029-105","doi-asserted-by":"crossref","unstructured":"Diels J, Neslusan C. Comparative Persistency With Newer Agents Used to Treat Type 2 Diabetes in the United States: Canagliflozin Versus Dipeptidyl Peptidase-4 Inhibitors and glucagon-Like Peptide-1 Agonists. Poster \u2013 The 20th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 16-20 May, 2015, Philadelphia, Pennsylvania.","DOI":"10.1016\/j.jval.2015.03.398"},{"key":"key-10.4103\/2230-8210.196029-106","first-page":"837","volume-title":"UK Prospective Diabetes Study (UKPDS) Group","author":"Intensive","year":"1998","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.196029-107","first-page":"1279","volume-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.196029-108","first-page":"159","volume-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-109","first-page":"1020","volume-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-110","first-page":"371","volume-title":"Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks","author":"Blonde","year":"2016","journal-title":"Postgrad Med"},{"key":"key-10.4103\/2230-8210.196029-111","first-page":"90","volume-title":"SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"key-10.4103\/2230-8210.196029-112","first-page":"S28","volume-title":"Adverse effects and safety of SGLT-2 inhibitors","author":"Halimi","year":"2014","journal-title":"Diabetes Metab"},{"key":"key-10.4103\/2230-8210.196029-113","first-page":"391","volume-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"key-10.4103\/2230-8210.196029-114","first-page":"426","volume-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","author":"Davies","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-115","doi-asserted-by":"crossref","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262-75.e9.","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"key-10.4103\/2230-8210.196029-116","first-page":"495","volume-title":"SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"key-10.4103\/2230-8210.196029-117","first-page":"429","volume-title":"Blood pressure reduction: An added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes","author":"Majewski","year":"2015","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-118","first-page":"101","volume-title":"Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors","author":"Patel","year":"2010","journal-title":"Curr Diab Rep"},{"key":"key-10.4103\/2230-8210.196029-119","first-page":"e22","volume-title":"Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability","author":"Nakatani","year":"2016","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-120","first-page":"16","volume-title":"Urinary and genital infections in patients with diabetes: How to diagnose and how to treat","author":"Njomnang","year":"2016","journal-title":"Diabetes Metab"},{"key":"key-10.4103\/2230-8210.196029-121","first-page":"409","volume-title":"Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes","author":"Arakaki","year":"2016","journal-title":"Postgrad Med"},{"key":"key-10.4103\/2230-8210.196029-122","first-page":"155","volume-title":"Balanitis and balanoposthitis: A review","author":"Edwards","year":"1996","journal-title":"Genitourin Med"},{"key":"key-10.4103\/2230-8210.196029-123","first-page":"373","volume-title":"Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria","author":"Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"key-10.4103\/2230-8210.196029-124","first-page":"905","volume-title":"Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors","author":"Gon\u00e7alves","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"key-10.4103\/2230-8210.196029-125","first-page":"262","volume-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/2230-8210.196029-126","first-page":"23","volume-title":"Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea","author":"Ji","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-127","first-page":"7","volume-title":"Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor","author":"Nicolle","year":"2014","journal-title":"Postgrad Med"},{"key":"key-10.4103\/2230-8210.196029-128","first-page":"597","volume-title":"Medication counselling with sodium glucose transporter 2 inhibitor therapy","author":"Kalra","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-129","first-page":"1","volume-title":"Guideline: Vulvovaginal candidosis (AWMF 015\/072), S2k (excluding chronic mucocutaneous candidosis)","author":"Mendling","year":"2015","journal-title":"Mycoses"},{"key":"key-10.4103\/2230-8210.196029-130","first-page":"615","volume-title":"2013 European guideline for the management of balanoposthitis","author":"Edwards","year":"2014","journal-title":"Int J STD AIDS"},{"key":"key-10.4103\/2230-8210.196029-131","first-page":"306","volume-title":"Management of recurrent vulvo-vaginal candidosis as a chronic illness","author":"Donders","year":"2010","journal-title":"Gynecol Obstet Invest"},{"key":"key-10.4103\/2230-8210.196029-132","first-page":"1039","volume-title":"Diabetes and balanoposthitis","author":"Kalra","year":"2016","journal-title":"J Pak Med Assoc"},{"key":"key-10.4103\/2230-8210.196029-133","unstructured":"EMA Confirms Recommendations to Minimise Ketoacidosis Risk with SGLT2 Inhibitors for Diabetes. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2016\/02\/news_detail_002477.jsp. [Last accessed on 2016 Jul 18]."},{"key":"key-10.4103\/2230-8210.196029-134","unstructured":"FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings about Too Much Acid in the Blood and Serious Urinary Tract Infections. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM475487.pdf. [Last accessed on 2016 Jul 18]."},{"key":"key-10.4103\/2230-8210.196029-135","unstructured":"FDA Drug Safety Communication: Interim Clinical Trial Results Find Increased Risk of Leg and Foot Amputations, Mostly Affecting the Toes, with the Diabetes Medicine Canagliflozin (Invokana, Invokamet); FDA to Investigate. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500965.htm. Last accessed on 2016 Jul 18]."},{"key":"key-10.4103\/2230-8210.196029-136","unstructured":"EMA Reviews Diabetes Medicine Canagliflozin. Review Follows Data on Toe Amputations in Ongoing Study. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors_Canagliflozin_20\/Procedure_started\/WC500204901.pdf. [Last accessed on 2016 Jul 18]."},{"key":"key-10.4103\/2230-8210.196029-137","first-page":"8","volume-title":"Possible adverse effects of SGLT2 inhibitors on bone","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key-10.4103\/2230-8210.196029-138","first-page":"962","volume-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"key-10.4103\/2230-8210.196029-139","unstructured":"EMEA \u2013 Bone Fractures with Canagliflozin. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors__20\/European_Commission_final_decision\/WC500206511.pdf. [Last accessed on 2016 Jul 18]."},{"key":"key-10.4103\/2230-8210.196029-140","unstructured":"Canagliflozin \u2013 Review of Bone Safety Data. FDA Briefing Document. NDA 204042. Endocrinologic and Metabolic Drugs Advisory Committee Meeting; 10 January, 2013. Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM334551.pdf. [Last accessed on 2016 Oct 20]."},{"key":"key-10.4103\/2230-8210.196029-141","doi-asserted-by":"crossref","unstructured":"Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: A network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 2016;18:1199-206. [Epub ahead of print].","DOI":"10.1111\/dom.12742"},{"key":"key-10.4103\/2230-8210.196029-142","first-page":"719578","volume-title":"A review on the relationship between SGLT2 inhibitors and cancer","author":"Lin","year":"2014","journal-title":"Int J Endocrinol"},{"key":"key-10.4103\/2230-8210.196029-143","first-page":"405","volume-title":"In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans","author":"Obermeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"key-10.4103\/2230-8210.196029-144","first-page":"294","volume-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-145","first-page":"1252","volume-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"key-10.4103\/2230-8210.196029-146","first-page":"1606","volume-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus","author":"Sarashina","year":"2014","journal-title":"Clin Ther"},{"key":"key-10.4103\/2230-8210.196029-147","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Glomerular Filtration Rate (GFR) Calculators. http:\/\/www.niddk.nih.gov\/health-information\/health-communication-programs\/nkdep\/lab-evaluation\/gfr-calculators\/Pages\/gfr-calculators.aspx [Last accessed on 2016 Jun 29]."},{"key":"key-10.4103\/2230-8210.196029-148","first-page":"899","volume-title":"Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance","author":"Botev","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key-10.4103\/2230-8210.196029-149","first-page":"33","volume-title":"A \u201cme-too\u201d of the dangerous dapagliflozin","author":"Canagliflozin","year":"2015","journal-title":"Prescrire Int"},{"key":"key-10.4103\/2230-8210.196029-150","first-page":"187","volume-title":"Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association","author":"Skyler","year":"2009","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.196029-151","unstructured":"FDA Briefing Document-Dapagliflozin. NDA 202293. Advisory Committee Meeting; 12 December, 2013. Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM378076.pdf. [Last accessed on 2016 Jul 18]."},{"key":"key-10.4103\/2230-8210.196029-152","doi-asserted-by":"crossref","unstructured":"Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. Acta Diabetol 2016. [Epub ahead of print].","DOI":"10.1007\/s00592-016-0922-5"},{"key":"key-10.4103\/2230-8210.196029-153","first-page":"1156","volume-title":"Diabetes in the desert: What do patients know about the heat?","author":"Nassar","year":"2010","journal-title":"J Diabetes Sci Technol"},{"key":"key-10.4103\/2230-8210.196029-154","unstructured":"John M, Violante R, Deerochanawong C, Vijapurkar U, Canovatchel W, Hamilton G. Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus Living in Hot Climates Poster \u2013 51st Annual Meeting of the European Association for The Study of Diabetes (EASD); 14-18 September, 2015, Stockholm, Sweden."},{"key":"key-10.4103\/2230-8210.196029-155","first-page":"577","volume-title":"Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement","author":"Kalra","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-156","first-page":"628","volume-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia","author":"Wan","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.196029-157","first-page":"874","volume-title":"Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow","author":"Kelwade","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-158","first-page":"30","volume-title":"Patient centred care in diabetology: An Islamic perspective from South Asia","author":"Niazi","year":"2012","journal-title":"J Diabetes Metab Disord"},{"key":"key-10.4103\/2230-8210.196029-159","first-page":"198","volume-title":"Fasts, feasts and festivals in diabetes-1: Glycemic management during Hindu fasts","author":"Kalra","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.196029-160","first-page":"231","volume-title":"American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement","author":"Bailey","year":"2016","journal-title":"Endocr Pract"},{"key":"key-10.4103\/2230-8210.196029-161","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes-2016: Summary of revisions. Diabetes care 2016;39 Suppl 1:S4-5.","DOI":"10.2337\/dc16-S003"},{"key":"key-10.4103\/2230-8210.196029-162","unstructured":"QRISK \u00ae 2-2016 Risk Calculator. Available from: https:\/\/www.qrisk.org\/. [Last accessed on 2016 Jul 11]."},{"key":"key-10.4103\/2230-8210.196029-163","first-page":"1669","volume-title":"Health risk calculators for Pakistan","author":"Kalra","year":"2016","journal-title":"J Pak Med Assoc"},{"key":"key-10.4103\/2230-8210.196029-164","unstructured":"QDiabetes \u00ae(Heart failure) \u2013 2015 Risk Calculator. Available from: http:\/\/www.qdiabetes.org\/heart-failure. [Last accessed on 2016 Jul 15]."}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:22:50Z","timestamp":1786713770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2230-8210.196029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":164,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"alternative-id":["196029"],"URL":"https:\/\/doi.org\/10.4103\/2230-8210.196029","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}